Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice
Journal of Diabetes Investigation · 2026
DOI: 10.1111/jdi.70363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2026. Verfasst von An-Jun Tan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Techno…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Liraglutide, Diabetic Cardiomyopathies. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Special Funds for the Yunnan Provincial Science and Technology Department-Kunming Medical University, Yunnan Revitalization Talent Support Program, Zhang Cuntai Expert Workstation of Yunnan Province.
Abstract (Originalsprache)
Background
Diabetic cardiomyopathy (DCM) and endothelial dysfunction are major drivers of cardiovascular morbidity in type 2 diabetes (T2DM). The present study investigates whether combined therapy with liraglutide (LIRA) and dapagliflozin (DAPA) provides synergistic cardioprotection and vascular improvement in a murine model of T2DM.
Methods
A murine model of T2DM was established by high‐fat diet feeding followed by low‐dose streptozotocin injection. Diabetic mice were treated for 4 weeks with LIRA, DAPA, or their combination. Echocardiographic analysis was performed to assess cardiac systolic function and structural parameters. Systemic metabolic parameters, cardiac injury biomarkers, histopathology, oxidative stress markers, and inflammation were assessed. Key signaling pathways were evaluated by Western blot and qPCR.
Results
Compared with monotherapies, combined LIRA and DAPA treatment produced superior metabolic improvements, including attenuated weight loss and enhanced glucose tolerance. The combination also more effectively reduced markers of myocardial injury (CK‐MB, LDH), diminished cardiac fibrosis, and preserved aortic architecture while inhibiting endothelial apoptosis. Mechanistically, co‐administration synergistically activated both the antioxidative NRF2/HO‐1 pathway and the vasoprotective AMPK/PKA‐eNOS axis, leading to a more comprehensive suppression of oxidative stress, inflammation, and apoptosis in cardiac and vascular tissues.
Conclusion
The combined use of LIRA and DAPA exerts synergistic cardioprotective and vasoprotective effects in a preclinical model of T2DM‐induced DCM. This synergistic effect may be mediated by the coordinated activation of the NRF2/HO‐1 and AMPK/PKA‐eNOS signaling pathways, leading to the attenuation of the key pathological drivers of diabetic cardiovascular injury. These findings provide a mechanistic rationale for the clinical exploration of GLP‐1RA and SGLT2i combination therapy in DCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatric Medicine, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
ORCID-Profile: An-Jun Tan, Tian-Rong Li
Förderung
- Joint Special Funds for the Yunnan Provincial Science and Technology Department-Kunming Medical University
- Yunnan Revitalization Talent Support Program
- Zhang Cuntai Expert Workstation of Yunnan Province
- Yunnan Clinical Medical Research Center for Geriatric Diseases
- Open Project of Clinical Medical Research Center of Yunnan First People's Hospital
- Open Project of Yunnan Provincial Spine & Spinal Cord Clinical Medical Center
Zitieren
APA
Tan, A. J., Li, T. R., Yang, J. J., Li, X. L., Li, W. Q., & Yu, J. W. (2026). Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70363
Vancouver
Tan AJ, Li TR, Yang JJ, Li XL, Li WQ, Yu JW. Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70363
BibTeX
@article{Tan2026,
author = {Tan, An-Jun and Li, Tian-Rong and Yang, Jing-Jing and Li, Xiao-Lu and Li, Wen-Qin and Yu, Jin-Wen},
title = {Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice},
journal = {Journal of Diabetes Investigation},
year = {2026},
doi = {10.1111/jdi.70363}
}
EUVIMED